Patents by Inventor Peter Brent Sampson
Peter Brent Sampson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11878980Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.Type: GrantFiled: August 27, 2021Date of Patent: January 23, 2024Assignee: UNIVERSITY HEALTH NETWORKInventors: Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
-
Patent number: 11667627Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: GrantFiled: February 10, 2021Date of Patent: June 6, 2023Assignee: UNIVERSITY HEALTH NETWORKInventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Publication number: 20220089601Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.Type: ApplicationFiled: August 27, 2021Publication date: March 24, 2022Inventors: Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
-
Publication number: 20220002313Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as a checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).Type: ApplicationFiled: July 12, 2021Publication date: January 6, 2022Inventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
-
Publication number: 20210269428Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: ApplicationFiled: February 10, 2021Publication date: September 2, 2021Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Patent number: 11104681Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.Type: GrantFiled: March 2, 2020Date of Patent: August 31, 2021Assignee: UNIVERSITY HEALTH NETWORKInventors: Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
-
Patent number: 11059832Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).Type: GrantFiled: December 6, 2019Date of Patent: July 13, 2021Assignee: UNIVERSITY HEALTH NETWORKInventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
-
Patent number: 10919886Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: GrantFiled: November 6, 2019Date of Patent: February 16, 2021Assignee: UNIVERSITY HEALTH NETWORKInventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Publication number: 20200270259Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.Type: ApplicationFiled: March 2, 2020Publication date: August 27, 2020Inventors: Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
-
Publication number: 20200190104Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).Type: ApplicationFiled: December 6, 2019Publication date: June 18, 2020Inventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
-
Publication number: 20200140428Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: ApplicationFiled: November 6, 2019Publication date: May 7, 2020Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Patent number: 10584130Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): (Formula (I)) wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.Type: GrantFiled: July 13, 2017Date of Patent: March 10, 2020Assignee: UNIVERSITY HEALTH NETWORKInventors: Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
-
Patent number: 10570143Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.Type: GrantFiled: October 9, 2018Date of Patent: February 25, 2020Assignee: UNIVERSITY HEALTH NETWORKInventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
-
Patent number: 10501474Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).Type: GrantFiled: June 23, 2016Date of Patent: December 10, 2019Assignee: University Health NetworkInventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
-
Patent number: 10472353Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: GrantFiled: April 19, 2019Date of Patent: November 12, 2019Assignee: University Health NetworkInventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Publication number: 20190292193Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): (Formula (I)) wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.Type: ApplicationFiled: July 13, 2017Publication date: September 26, 2019Inventors: Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
-
Patent number: 10392374Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: GrantFiled: February 1, 2018Date of Patent: August 27, 2019Assignee: University Health NetworkInventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Publication number: 20190248775Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: ApplicationFiled: April 19, 2019Publication date: August 15, 2019Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Patent number: 10358436Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.Type: GrantFiled: February 22, 2018Date of Patent: July 23, 2019Assignee: University Health NetworkInventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
-
Patent number: RE47731Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.Type: GrantFiled: March 6, 2018Date of Patent: November 19, 2019Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel